

The use of intravesical lignocaine to reduce pain and increase dwell time of intravesical mitomycin chemotherapy

Submission date 12/09/2003	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 12/09/2003	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 13/02/2018	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr S Williams

Contact details

Southern Derbyshire Acute Hospitals NHS Trust
Surgery & Urology Department
Derby City General Hospital
Uttoxeter Road
Derby
United Kingdom
DE22 3NE
+44 (0)1332 340131 ext. 5538
simon_wi@hotmail.com

Additional identifiers

Protocol serial number

N0077120719

Study information

Scientific Title

The use of intravesical lignocaine to reduce pain and increase dwell time of intravesical mitomycin chemotherapy

Study objectives

Does intravesical lignocaine reduce the pain and maximise the dwell time of intravesical mitomycin?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Analgesia for intravesical mitomycin chemotherapy

Interventions

30 min before mitomycin is instilled into the patients bladder, 40 ml 0.5% lignocaine or 40 ml saline (placebo) will be instilled. The catheter will then be clamped. After 30 min, the lignocaine /placebo will be drained and mitomycin instilled. Visual analogue scores of pain will be taken at 30, 60 and 120 min (or at first void if sooner). The time that the mitomycin is tolerated will be noted.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Mitomycin, lignocaine

Primary outcome(s)

Visual analogue pain scores. Dwell time.

Key secondary outcome(s)

Not provided at time of registration

Completion date

10/11/2003

Eligibility

Key inclusion criteria

Patients with transitional cell carcinoma of the bladder, following their first endoscopic resection.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

10/03/2003

Date of final enrolment

10/11/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Southern Derbyshire Acute Hospitals NHS Trust

Derby

United Kingdom

DE22 3NE

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Charity

Funder Name

Southern Derbyshire Acute Hospitals NHS Trust (NHS R&D Support Funding) + charitable funds

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration